NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Published:2023-10 Issue:10409 Volume:402 Page:1272-1281
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Wainberg Zev A,Melisi Davide,Macarulla Teresa,Pazo Cid Roberto,Chandana Sreenivasa R,De La Fouchardière Christelle,Dean Andrew,Kiss Igor,Lee Woo Jin,Goetze Thorsten O,Van Cutsem Eric,Paulson A Scott,Bekaii-Saab Tanios,Pant Shubham,Hubner Richard A,Xiao Zhimin,Chen Huanyu,Benzaghou Fawzi,O'Reilly Eileen M

Funder

Ipsen Biopharmaceuticals Inc

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Epidemiology of pancreatic cancer: global trends, etiology and risk factors;Rawla;World J Oncol,2019

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas;Goldstein;J Clin Oncol,2014

5. Treatment landscape of metastatic pancreatic cancer;De Dosso;Cancer Treat Rev,2021

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response;Translational Oncology;2024-11

2. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-10

3. Metastatic pancreatic cancer: a new standardised dose-reduction regimen?;The Lancet Gastroenterology & Hepatology;2024-10

4. Synthesis and Structure of 5-Methyl-9-(trifluoromethyl)-12H-quino[3,4-b][1,4]benzothiazinium Chloride as Anticancer Agent;Molecules;2024-09-12

5. Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien;Deutsches Ärzteblatt Online;2024-09-06